US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jul 2, 2013 (13 years ago)

Atomoxetine HCL

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Label Mixup: ATOMOXETINE HCL, Capsule, 80 mg may be potentially mis-labeled as one of the following drugs: ATOMOXETINE HCL, Capsule, 18 mg, NDC 00002323830, Pedigree: AD30140_16, EXP: 5/7/2014; PRENATAL MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg, NDC 00904531360, Pedigree: W003706, EXP: 6/25/2014; RANOLAZINE ER, Tablet, 500 mg, NDC 61958100301, Pedigree: AD60272_40, EXP: 5/22/2014; PRO

What was recalled

ATOMOXETINE HCL, Capsule, 80 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00002325030.

Recalling firm
Aidapak Services, LLC
Origin
WA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-768-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Atomoxetine recalls

See all
Class II · Moderate risk Ongoing

Atomoxetine Capsules HCL

Reason Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.

Safecor Health, LLC D-0538-2026
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-761-01 D-0244-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-760-01 D-0243-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-759-01 D-0242-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-758-01 D-0241-2025